PMID: 8590785Oct 1, 1995Paper

Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy

Acta Diabetologica
N FukaseH Sasaki

Abstract

Gastric inhibitory polypeptide (tGIP) and truncated glucagon like peptide-1 (GLP-1) are potent gastrointestinal insulinotropic factors (incretin), are most released after a meal or ingestion of glucose in man and animals. To investigate whether sulfonylurea (SU) affects the secretion of incretin, the modulation of plasma GIP and tGLP-1 levels following glucose ingestion in non-insulin-dependent diabetic type 2 patients with or without SU therapy was studied. A 75-G oral glucose tolerance test (OGTT) was carried out on 9 healthy subjects (controls) and 18 patients with non-obese type 2, 9 of whom were treated by diet alone (NIDDM-diet) and the other 9 with SU (glibenclamide 2.5 mg or gliclazide 40 mg) once a day (NIDDM-SU). Plasma GIP was measured by radioimmunoassay (RIA) with R65 antibody, and GLP-1 was measured by RIA with N-terminal-directed antiserum R1043 (GLP-1NT) and C-terminal-directed antiserum R2337 (GLP-1CT). Following OGTT, plasma glucose, GIP, GLP-1NT, and GLP-1CT in type 2 patients increased more markedly than in controls, despite the lower response of insulin. However, there were no significant differences in plasma levels of these peptides between the NIDDM-diet and NIDDM-SU groups. Therefore, it is unlikely tha...Continue Reading

References

Aug 1, 1974·The Journal of Clinical Endocrinology and Metabolism·S CatalandE L Mazzaferri
Jul 16, 1970·The New England Journal of Medicine·W A MüllerR H Unger
May 1, 1981·The Journal of Clinical Endocrinology and Metabolism·J S CoxeS E Crockett
Jan 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·N FukaseH Sasaki
Jul 10, 1957·Annals of the New York Academy of Sciences·H T RICKETTSH SCHMID

❮ Previous
Next ❯

Citations

Jul 19, 2002·Journal of Cellular Physiology·Erin B RamshurBurton M Wice
Aug 28, 2002·Diabetes·Frank Reimann, Fiona M Gribble
Dec 22, 1999·Endocrine Reviews·T J Kieffer, J F Habener
Jul 12, 2019·Endocrinology, Diabetes & Metabolism·Yuki FujiwaraKinsuke Tsuda
Dec 19, 2016·Nutrition & Metabolism·Alexandra M BodnarucIsabelle Giroux
Mar 15, 2015·American Journal of Physiology. Gastrointestinal and Liver Physiology·Robert L DobbinsChari D Smith
Apr 29, 2010·American Journal of Physiology. Endocrinology and Metabolism·Filip K Knop
Jan 9, 2018·Mayo Clinic Proceedings·Sofie HædersdalTina Vilsbøll
Sep 2, 2019·Dermatology : International Journal for Clinical and Investigative Dermatology·Maeve LynchBrian Kirby

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.